Novel genetic and epigenetic alterations in ... - Ous-research.no

Journal of Translational Medicine 2008, 6:13http://www.translational-medicine.com/content/6/1/13Norwegian Cancer Society (grant A95068, RAL). The study is also supportedby grants from the Norwegian Research Council (163962/V50, RALand 161448/V40, RAL). MAA is supported by grants from the Ministerio deEducación y Ciencia (BFU2006-01925; GEN2003-20662-C07-02).Lack of MAL protein expression in colorectal carcinomasFigure 6Lack of MAL protein expression in colorectal carcinomas.Positive cytoplasmic staining of MAL was found inkidney tubuli (A), and no staining was observed in heart muscle(B), in agreement with earlier reports [30]. The epithelialcells of colorectal carcinomas were MAL negative (C, D),whereas in normal colon tissue, cytoplasmic expression ofMAL was found in both epithelia and connective tissue (E, F).All images were captured using the 40× lens (400× magnification).colon cancer cell lines with epigenetic drugs. MAA providedthe antibody for immunohistochemical analysesand contributed with scientific discussion. AK providedseveral of the cancer cell lines. GIM and TOR have collectedthe series of human primary carcinomas and normalmucosa tissue and provided all clinical andpathological information regarding these samples. RISgenerated the tissue microarray and contributed in manuscriptpreparations. ETE has provided the series of adenomasamples and provided all clinical and pathologicalinformation regarding these samples and contributed inmanuscript preparations. RAL conceived the study, participatedin its design, contributed in evaluation of results,scientific discussion and in manuscript preparation. Allauthors have read and approved the final manuscript.AcknowledgementsWe are grateful to Vera M. Abeler for evaluating the immunohistochemicalstaining of the TMA tissue cores and to Stine Aske Danielsen for technicalassistance. GEL is a post doc and MB is a PhD student supported by theReferences1. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitororigin of human cancer. Nat Rev Genet 2006, 7:21-33.2. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, JessupJM, Kolodner R: Methylation of the hMLH1 promoter correlateswith lack of expression of hMLH1 in sporadic colontumors and mismatch repair-defective human tumor celllines. Cancer Res 1997, 57:808-811.3. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, MarkowitzS, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD,Vogelstein B, Kunkel TA, Baylin SB: Incidence and functional consequencesof hMLH1 promoter hypermethylation in colorectalcarcinoma. Proc Natl Acad Sci U S A 1998, 95:6870-6875.4. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, BurgartLJ, Thibodeau SN: Hypermethylation of the hMLH1 promoterin colon cancer with microsatellite instability. CancerRes 1998, 58:3455-3460.5. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, PeinadoMA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB,Herman JG: Analysis of adenomatous polyposis coli promoterhypermethylation in human cancer. Cancer Res 2000,60:4366-4371.6. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, SchorderetD, Bosman FT, Chaubert P: Methylation silencing andmutations of the p14ARF and p16INK4a genes in colon cancer.Lab Invest 2001, 81:217-229.7. Laird PW: The power and the promise of DNA methylationmarkers. Nat Rev Cancer 2003, 3:253-266.8. Müller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M,Mühlthaler M, Ofner D, Margreiter R, Widschwendter M: Methylationchanges in faecal DNA: a marker for colorectal cancerscreening? Lancet 2004, 363:1283-1285.9. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, LuS, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, WillsonJK, Rao JS, Shuber A, Markowitz SD: Detection in fecal DNA ofcolon cancer-specific methylation of the nonexpressedvimentin gene. J Natl Cancer Inst 2005, 97:1124-1132.10. Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H,Sturzl M, Hohenberger W, Matzel KE: DNA Stool Test for ColorectalCancer: Hypermethylation of the Secreted Frizzled-Related Protein-1 Gene. Dis Colon Rectum 2007.11. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, RognumTO, Lothe RA: ADAMTS1, CRABP1, and NR3C1 identified asepigenetically deregulated genes in colorectal tumorigenesis.Cell Oncol 2006, 28:259-272.12. Lind GE, Ahlquist T, Lothe RA: DNA hypermethylation of MAL:a promising diagnostic biomarker for colorectal tumors.Gastroenterology 2007, 132:1631-1632.13. Puertollano R, Martin-Belmonte F, Millan J, de Marco MC, Albar JP,Kremer L, Alonso MA: The MAL proteolipid is necessary fornormal apical transport and accurate sorting of the influenzavirus hemagglutinin in Madin-Darby canine kidney cells. J CellBiol 1999, 145:141-151.14. Tugores A, Rubio T, Rancano C, Alonso MA: A tandem array ofSp-1 sites and a reverse initiator element are both requiredfor synergistic transcriptional activation of the T-cell-specificMAL gene. DNA Cell Biol 1997, 16:245-255.15. Alonso MA, Weissman SM: cDNA cloning and sequence of MAL,a hydrophobic protein associated with human T-cell differentiation.Proc Natl Acad Sci U S A 1987, 84:1997-2001.16. Marazuela M, Alonso MA: Expression of MAL and MAL2, twoelements of the protein machinery for raft-mediated transport,in normal and neoplastic human tissue. Histol Histopathol2004, 19:925-933.17. Mimori K, Shiraishi T, Mashino K, Sonoda H, Yamashita K, YoshinagaK, Masuda T, Utsunomiya T, Alonso MA, Inoue H, Mori M: MALgene expression in esophageal cancer suppresses motility,invasion and tumorigenicity and enhances apoptosis throughthe Fas pathway. Oncogene 2003, 22:3463-3471.Page 10 of 11(page number not for citation purposes)